Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Edgar Gonzalez-Kozlova *Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6948-0626
Swapnil Tichkule *Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-2940-9961
Yohei Nose *Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tzu-Yi Chen *Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Eduard ReznikDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Juliet V SantiagoDepartment of Biochemistry and Neurology, Emory University, Atlanta, GA, USA.
Anish KorrapatiDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Taliah SoleymaniDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Roman KosoyDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3080-7900
Igor FigueiredoDepartment of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Donghoon LeeDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-0453-6059
Gabriel E HoffmanDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0957-0224
Natasha KyprianouDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8713-3599
Ronald E GordonDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carlos Cordon-CardoDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-0858-5624
Srikant RangarajuDepartment of Neurology, Yale University, New Haven, CT, USA.ORCID 0000-0003-2765-1500
Nicholas T SeyfriedDepartment of Biochemistry and Neurology, Emory University, Atlanta, GA, USA.ORCID 0000-0002-4507-624X
Vahram HaroutunianCenter for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA.ORCID 0000-0001-5860-2512
John F FullardDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-9874-2907
Panos RoussosDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.ORCID 0000-0002-4640-6239
Navneet DograDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. navneet.dogra@mssm.edu.ORCID 0000-0002-4602-3991
Funding
Higher Order Chromatin and Genetic Risk for Alzheimer's DiseaseR01AG050986 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROUSSOS, PANAGIOTIS · 2015 to 2025
$11.2M
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer DiseaseR01AG065582 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, ROUSSOS, PANAGIOTIS · 2020 to 2024
$9.9M
The adaptive-innate immune interactome across multiple tissues in Alzheimer's diseaseR01AG082185 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI VAHRAM HAROUTUNIAN, Donghoon Lee · 2023 to 2026
$9.0M
The BrainCellQTL consortium: QTL mapping in the human brain at the single cell levelU24AG087563 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Panagiotis Roussos · 2024 to 2026
$7.2M
Neuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer’s diseaseR01AG075820 · NIA · YALE UNIVERSITY · PI RANGARAJU, SRIKANT, SEYFRIED, NICHOLAS THOMAS · 2021 to 2025
$5.1M
Molecular Profiling of the Tumor Microenvironment in Prostate Cancer ProgressionR01CA296581 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Navneet Dogra, Natasha Kyprianou · 2025 to 2026
$1.4M
Disparities in molecular testing among non-small cell lung cancer patientsP20CA264076 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENN, EMMA KATHERINE TARA · 2021 to 2024
$1.2M
Delineating the RNA cargo of exosomes from brain microenvironmentR21AG078848 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DOGRA, NAVNEET · 2022 to 2022
$464k
Exosomes: A Novel Contributor of Microglia-Mediated Neuroinflammation and Neurodegeneration.F31NS127530 · NINDS · EMORY UNIVERSITY · PI SANTIAGO, JULIET VICTORIA · 2022 to 2023
$85k
NCI NIH HHS P20 CA264076NCI NIH HHS R01 CA296581NIA NIH HHS R01 AG050986NIA NIH HHS R01 AG065582NIA NIH HHS R01 AG075820NIA NIH HHS R01 AG082185NIA NIH HHS R21 AG078848NIA NIH HHS U24 AG087563NINDS NIH HHS F31 NS127530U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) NIH R21 AGO78848
6 · The paper itself
Abstract
Cells release heterogeneous extracellular vesicles and particles (EVPs) into circulation, carrying RNA and proteins that reflect their origin. Recently, brain-derived EVs have gained significant attention as non-invasive biomarkers for Alzheimer's disease (AD). Here, we identified sub-50nm extracellular nanoparticles in human brain and blood that lack the hallmarks of small EVs, exosomes, exomeres, and supermeres but are enriched for brain-specific markers, hereafter termed small EPs or 'SECmeres'. We discovered that RNAs associated with SECmeres discriminated AD cases from controls with higher significance than small EVs, large EVs showed no differences. Discriminating RNAs were enriched in small EVs (Synaptotagmin, Alpha-synuclein, MAPT) or SECmeres (L1CAM, Syntaxin, Neurogranin), indicating distinct brain-derived signatures. Single-cell RNAseq deconvolution shows small EVs contain RNAs from diverse brain cells, whereas SECmeres enrich brain endothelial transcripts, lining cerebral blood vessels and forming the blood-brain barrier (BBB). These findings challenge the prevailing view that small EVs are the primary carriers of biomarkers. Collectively, our study shows that blood EVPs carry brain-specific information for liquid biopsy, pending validation in larger blinded clinical trials.
Indexed as
Alzheimer DiseaseBiomarkersExtracellular VesiclesRNAAgedAged, 80 and overBlood-Brain BarrierBrainFemaleHumansMaleBiomarkersRNA
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease. · full record | OpenQuestion